Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116


Genomic alterations in neuroendocrine cancers of the ovary.

Yaghmour G, Prouet P, Wiedower E, Jamy OH, Feldman R, Chandler JC, Pandey M, Martin MG.

J Ovarian Res. 2016 Aug 26;9(1):52. doi: 10.1186/s13048-016-0259-2.


Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.

McCullar B, Pandey M, Yaghmour G, Hare F, Patel K, Stein K, Feldman R, Chandler JC, Martin MG.

Breast Cancer Res Treat. 2016 Jul;158(1):195-202. doi: 10.1007/s10549-016-3867-z. Epub 2016 Jun 21. Erratum in: Breast Cancer Res Treat. 2019 Jan;173(1):243.


Population-based Analysis of the Clinical Features of Primary Small Cell Carcinoma of the Ovary.

Jamy O, Yaghmour G, Hare F, Martin MG.

Anticancer Res. 2015 May;35(5):3091-5.


Identification of molecular targets in vulvar cancers.

Palisoul ML, Mullen MM, Feldman R, Thaker PH.

Gynecol Oncol. 2017 Aug;146(2):305-313. doi: 10.1016/j.ygyno.2017.05.011. Epub 2017 May 20.


Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.

Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, Won H, Halpenny DF, Wang H, Tian SK, Litvak AM, Paik PK, Drilon AE, Socci N, Poirier JT, Shen R, Berger MF, Moreira AL, Travis WD, Rudin CM, Ladanyi M.

Clin Cancer Res. 2016 Jul 15;22(14):3618-29. doi: 10.1158/1078-0432.CCR-15-2946. Epub 2016 Mar 9.


Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.

Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D, Miller VA, Kris MG, Ladanyi M, Rizvi NA.

Clin Cancer Res. 2015 Aug 15;21(16):3631-9. doi: 10.1158/1078-0432.CCR-14-2683. Epub 2015 Jan 7.


Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.

Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakkum-Gamez J, McAlpine JN, Anglesio MS.

BMC Cancer. 2015 May 19;15:415. doi: 10.1186/s12885-015-1421-8.


Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.

Ali SM, Pal SK, Wang K, Palma NA, Sanford E, Bailey M, He J, Elvin JA, Chmielecki J, Squillace R, Dow E, Morosini D, Buell J, Yelensky R, Lipson D, Frampton GM, Howley P, Ross JS, Stephens PJ, Miller VA.

Oncologist. 2016 Jan;21(1):33-9. doi: 10.1634/theoncologist.2015-0241. Epub 2015 Dec 15.


Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.

Simbolo M, Mafficini A, Sikora KO, Fassan M, Barbi S, Corbo V, Mastracci L, Rusev B, Grillo F, Vicentini C, Ferrara R, Pilotto S, Davini F, Pelosi G, Lawlor RT, Chilosi M, Tortora G, Bria E, Fontanini G, Volante M, Scarpa A.

J Pathol. 2017 Mar;241(4):488-500. doi: 10.1002/path.4853. Epub 2016 Dec 29.


Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.

Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, Stephens PJ.

Cancer. 2016 Sep 1;122(17):2654-62. doi: 10.1002/cncr.30102. Epub 2016 Jun 10.


A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy.

Weiss GJ, Byron SA, Aldrich J, Sangal A, Barilla H, Kiefer JA, Carpten JD, Craig DW, Whitsett TG.

PLoS One. 2017 Jun 6;12(6):e0179170. doi: 10.1371/journal.pone.0179170. eCollection 2017.


Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.

Meagher NS, Schuster K, Voss A, Budden T, Pang CNI, deFazio A, Ramus SJ, Friedlander ML.

Gynecol Oncol. 2018 Sep;150(3):527-533. doi: 10.1016/j.ygyno.2018.07.013. Epub 2018 Jul 25.


Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer.

Ross JS, Wang K, Elkadi OR, Tarasen A, Foulke L, Sheehan CE, Otto GA, Palmer G, Yelensky R, Lipson D, Chmielecki J, Ali SM, Elvin J, Morosini D, Miller VA, Stephens PJ.

J Clin Pathol. 2014 Sep;67(9):772-6.


Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.

Mahdi H, Xiu J, Reddy SK, DeBernardo R.

J Surg Oncol. 2015 Aug;112(2):188-94. doi: 10.1002/jso.23993. Epub 2015 Aug 7.


The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma.

Cooke SL, Ennis D, Evers L, Dowson S, Chan MY, Paul J, Hirschowitz L, Glasspool RM, Singh N, Bell S, Day E, Kochman A, Wilkinson N, Beer P, Martin S, Millan D, Biankin AV, McNeish IA; Scottish Genomes Partnership.

Clin Cancer Res. 2017 Dec 15;23(24):7633-7640. doi: 10.1158/1078-0432.CCR-17-1789. Epub 2017 Sep 27.


Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung.

Miyoshi T, Umemura S, Matsumura Y, Mimaki S, Tada S, Makinoshima H, Ishii G, Udagawa H, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Aokage K, Hishida T, Yoshida J, Nagai K, Goto K, Tsuboi M, Tsuchihara K.

Clin Cancer Res. 2017 Feb 1;23(3):757-765. doi: 10.1158/1078-0432.CCR-16-0355. Epub 2016 Aug 9.


Identification of Driver Mutations in Rare Cancers: The Role of SMARCA4 in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT).

Lang JD, Hendricks WPD.

Methods Mol Biol. 2018;1706:367-379. doi: 10.1007/978-1-4939-7471-9_20. Review.


Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.

El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S.

Cancer Biol Ther. 2015;16(12):1726-37. doi: 10.1080/15384047.2015.1113356.


Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.

Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, Miller VA, Zajchowski D, Shawver LK, Stephens PJ.

Gynecol Oncol. 2013 Sep;130(3):554-9. doi: 10.1016/j.ygyno.2013.06.019. Epub 2013 Jun 20.


Expression in human lung cancer cell lines of genes of prohormone processing and the neuroendocrine phenotype.

Vos MD, Scott FM, Iwai N, Treston AM.

J Cell Biochem Suppl. 1996;24:257-68.


Supplemental Content

Support Center